SICOR Announces Approval of G-CSF in Lithuania
"This approval will provide greater access to a product with a proven track record of clinical success at an affordable cost to patients and health payers in Lithuania," stated Marvin Samson, president and chief executive officer. "This latest approval also provides an important addition to our growing biotechnology portfolio in Eastern Europe and demonstrates our commitment to bringing these important products to market in Eastern Europe and eventually, around the world."
Filgrastim is used to stimulate the growth of white blood cells that help to fight infections. The administration of filgrastim may reduce the duration of neutropenia (low white blood cell counts). The branded product, NEUPOGEN(R), is marketed by Amgen Inc.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.